Christopher B. Granger, MD, FACC
Professor of Medicine and Nursing
Duke Clinical Research Institute

Printed as of 11/18/2026

Disclosures

Personal Commercial (21)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Abiomed	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*
Alnylam	Research/Research Grants	Significant (>= $5,000)	
Alnylam Pharm.	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*
Amgen Inc.	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Amgen Inc.	Consultant Fees/Honoraria	Modest (< $5,000)	
Boston Scientific	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Bristol Myers Squibb	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Cardionomic	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
CeleCor	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Janssen	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Janssen Pharmaceuticals	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
NIH	Research/Research Grants ‡ *RACE CARS*	Significant (>= $5,000)	*Arrhythmias and Clinical EP General Cardiology*
Novartis Corporation	Research/Research Grants	Significant (>= $5,000)	
Pfizer	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*
Philips	Research/Research Grants	Significant (>= $5,000)	
Rhoshan Pharmaceuticals, INC.	Consultant Fees/Honoraria	Modest (< $5,000)	
Roche	Research/Research Grants	Significant (>= $5,000)	
Tenac.io	Stock	Modest (< $5,000)	*General Cardiology*
Veralox Therapeutics, Inc.	Consultant Fees/Honoraria	Modest (< $5,000)	
Spouse/Domestic Partner/Immediate Household Member			
Novartis Corporation	Research/Research Grants	Significant (>= $5,000)	*General Cardiology*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

Non-Commercial Enity Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
FDA	Research/Research Grants	Significant (>= $5,000)	
National Institutes of Health	Consultant Fees/Honoraria	Significant (>= $5,000)	

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/19/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/19/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/19/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/19/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.